A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2017
At a glance
- Drugs PRX 3140 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors EPIX Pharmaceuticals
- 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
- 17 Jan 2008 Amended results were reported in a EPIX Pharmaceuticals media release.
- 19 Dec 2007 Status changed from in progress to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History